Reporting Manager
Madison Avenue International LP
Symbol
KROS
Shares outstanding
30,507,667 shares
Disclosed Ownership
823,707 shares
Ownership
2.7%
Form type
SCHEDULE 13G/A
Filing time
17 Feb 2026, 16:52:19 UTC
Date of event
31 Dec 2025
Previous filing
14 May 2025

Key filing fact

Madison Avenue Partners, LP disclosed 2.7% ownership in Keros Therapeutics, Inc. Common Stock, $0.0001 par value per share (the "Common Stock") (KROS) on 31 Dec 2025.

Key facts

  • Madison Avenue Partners, LP filed SCHEDULE 13G/A for Keros Therapeutics, Inc. Common Stock, $0.0001 par value per share (the "Common Stock") (KROS).
  • Disclosed ownership: 2.7%.
  • Date of event: 31 Dec 2025.

Change

  • Previous schedule filing date: 14 May 2025.
  • Current filing was accepted on 17 Feb 2026, 16:52.

Research use

  • This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
  • You can verify ownership claims directly against the original SEC filing.

Evidence

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

See Original Filing

Reporting persons

Reporting managers (6)

Names, ownership, voting power, signatures, titles, and CIKs as disclosed in this Schedule 13D/G filing.

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
Madison Avenue International LP 2.7% 823,707 0 823,707 /s/ Eli Samaha Eli Samaha, as Manager of Madison Avenue GP, LLC, the General Partner of Madison Avenue International LP
Madison Avenue Partners, LP 2.7% 823,707 0 823,707 /s/ Eli Samaha Eli Samaha, as Managing Member of EMAI Management, LLC, the General Partner of Madison Avenue Partners, LP
EMAI Management, LLC 2.7% 823,707 0 823,707 /s/ Eli Samaha Eli Samaha, as Managing Member
Madison Avenue GP, LLC 2.7% 823,707 0 823,707 /s/ Eli Samaha Eli Samaha, as Manager
Caraway Jackson Investments LLC 2.7% 823,707 0 823,707 /s/ Eli Samaha Eli Samaha, as Member
Eli Samaha 2.7% 823,707 0 823,707 /s/ Eli Samaha ELI SAMAHA
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .